

# Mitchell K P Lai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1285750/publications.pdf>

Version: 2024-02-01

84  
papers

3,336  
citations

156536

32  
h-index

190340

53  
g-index

91  
all docs

91  
docs citations

91  
times ranked

6176  
citing authors

#	ARTICLE	IF	CITATIONS
1	Elevation of inactive cleaved annexin A1 in the neocortex is associated with amyloid, inflammatory and apoptotic markers in neurodegenerative dementias. <i>Neurochemistry International</i> , 2022, 152, 105251.	1.9	8
2	Pathophysiology of blood brain barrier dysfunction during chronic cerebral hypoperfusion in vascular cognitive impairment. <i>Theranostics</i> , 2022, 12, 1639-1658.	4.6	72
3	The role of inflammasomes in vascular cognitive impairment. <i>Molecular Neurodegeneration</i> , 2022, 17, 4.	4.4	43
4	The lateral entorhinal cortex is a hub for local and global dysfunction in early Alzheimer's disease states. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 1616-1631.	2.4	6
5	AIM2 inflammasome mediates hallmark neuropathological alterations and cognitive impairment in a mouse model of vascular dementia. <i>Molecular Psychiatry</i> , 2021, 26, 4544-4560.	4.1	71
6	Isoform-specific upregulation of FynT kinase expression is associated with tauopathy and glial activation in Alzheimer's disease and Lewy body dementias. <i>Brain Pathology</i> , 2021, 31, 253-266.	2.1	21
7	Preclinical and Clinical Evidence for the Involvement of Sphingosine 1-Phosphate Signaling in the Pathophysiology of Vascular Cognitive Impairment. <i>NeuroMolecular Medicine</i> , 2021, 23, 47-67.	1.8	6
8	Plasma osteopontin as a biomarker of Alzheimer's disease and vascular cognitive impairment. <i>Scientific Reports</i> , 2021, 11, 4010.	1.6	43
9	Plasma $\tau_{181}$ to $A\beta_{42}$ ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1649-1662.	0.4	37
10	The noncanonical chronicles: Emerging roles of sphingolipid structural variants. <i>Cellular Signalling</i> , 2021, 79, 109890.	1.7	8
11	Hippocampal transcriptome profiling reveals common disease pathways in chronic hypoperfusion and aging. <i>Aging</i> , 2021, 13, 14651-14674.	1.4	5
12	Blood-Based Cardiac Biomarkers and the Risk of Cognitive Decline, Cerebrovascular Disease, and Clinical Events. <i>Stroke</i> , 2021, 52, 2275-2283.	1.0	15
13	Intermittent fasting attenuates inflammasome-associated apoptotic and pyroptotic death in the brain following chronic hypoperfusion. <i>Neurochemistry International</i> , 2021, 148, 105109.	1.9	8
14	Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1231-1241.	0.9	51
15	AIM2 inflammasome mediates apoptotic and pyroptotic death in the cerebellum following chronic hypoperfusion. <i>Experimental Neurology</i> , 2021, 346, 113856.	2.0	12
16	Low plasma ergothioneine levels are associated with neurodegeneration and cerebrovascular disease in dementia. <i>Free Radical Biology and Medicine</i> , 2021, 177, 201-211.	1.3	32
17	O-GlcNAcylation as a Therapeutic Target for Alzheimer's Disease. <i>NeuroMolecular Medicine</i> , 2020, 22, 171-193.	1.8	32
18	Immunomodulatory sphingosine-1-phosphates as plasma biomarkers of Alzheimer's disease and vascular cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 122.	3.0	19

#	ARTICLE	IF	CITATIONS
19	Blood-based cardiac biomarkers and the risk of cognitive decline, vascular events and mortality. <i>Alzheimer's and Dementia</i> , 2020, 16, e041689.	0.4	0
20	Lysosomal cathepsin D is upregulated in Alzheimer's disease neocortex and may be a marker for neurofibrillary degeneration. <i>Brain Pathology</i> , 2019, 29, 63-74.	2.1	48
21	Sphingolipidomics analysis of large clinical cohorts. Part 2: Potential impact and applications. <i>Biochemical and Biophysical Research Communications</i> , 2018, 504, 602-607.	1.0	9
22	Sphingolipidomics analysis of large clinical cohorts. Part 1: Technical notes and practical considerations. <i>Biochemical and Biophysical Research Communications</i> , 2018, 504, 596-601.	1.0	11
23	Serum Hepatocyte Growth Factor Is Associated with Small Vessel Disease in Alzheimer's Dementia. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 8.	1.7	17
24	S-Nitrosylation of Divalent Metal Transporter 1 Enhances Iron Uptake to Mediate Loss of Dopaminergic Neurons and Motoric Deficit. <i>Journal of Neuroscience</i> , 2018, 38, 8364-8377.	1.7	24
25	Serum IL-8 is a marker of white matter hyperintensities in patients with Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 7, 41-47.	1.2	34
26	Selective induction of alternatively spliced FynT isoform by TNF facilitates persistent inflammatory responses in astrocytes. <i>Scientific Reports</i> , 2017, 7, 43651.	1.6	16
27	Increased Transforming Growth Factor $\beta 2$ in the Neocortex of Alzheimer's Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble $A\beta 42$ Load. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 157-166.	1.2	25
28	Relaxin the brain: a case for targeting the nucleus incertus network and relaxin/RXFP3 system in neuropsychiatric disorders. <i>British Journal of Pharmacology</i> , 2017, 174, 1061-1076.	2.7	48
29	Mitochondrial Translocase of the Outer Membrane Alterations May Underlie Dysfunctional Oxidative Phosphorylation in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 793-801.	1.2	19
30	[P1456]: INCREASED PSER129 $\pm$ SYNNUCLEIN IS ASSOCIATED WITH SYNAPTIC DEFICITS IN DEMENTIA WITH LEWY BODIES. <i>Alzheimer's and Dementia</i> , 2017, 13, P461.	0.4	0
31	An iTRAQ-based proteomic analysis reveals dysregulation of neocortical synaptopodin in Lewy body dementias. <i>Molecular Brain</i> , 2017, 10, 36.	1.3	25
32	Andrographolide induces Nrf2 and heme oxygenase 1 in astrocytes by activating p38 MAPK and ERK. <i>Journal of Neuroinflammation</i> , 2016, 13, 251.	3.1	65
33	Biological Effects of Naturally Occurring Sphingolipids, Uncommon Variants, and Their Analogs. <i>NeuroMolecular Medicine</i> , 2016, 18, 396-414.	1.8	27
34	An isoform-specific role of FynT tyrosine kinase in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2016, 136, 637-650.	2.1	20
35	Muscarinic M1 Receptor Coupling to G-protein is Intact in Parkinson's Disease Dementia. <i>Journal of Parkinson's Disease</i> , 2016, 6, 733-739.	1.5	3
36	Growth differentiation factor-15 and white matter hyperintensities in cognitive impairment and dementia. <i>Medicine (United States)</i> , 2016, 95, e4566.	0.4	46

#	ARTICLE	IF	CITATIONS
37	Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with $\beta^2$ -amyloid burden and synaptic deficits in Lewy body dementias. <i>Molecular Brain</i> , 2016, 9, 84.	1.3	26
38	Andrographolide attenuates LPS-stimulated up-regulation of C-C and C-X-C motif chemokines in rodent cortex and primary astrocytes. <i>Journal of Neuroinflammation</i> , 2016, 13, 34.	3.1	24
39	Gender differences in white matter pathology and mitochondrial dysfunction in Alzheimer's disease with cerebrovascular disease. <i>Molecular Brain</i> , 2016, 9, 27.	1.3	58
40	Sphingosine kinase inhibition ameliorates chronic hypoperfusion-induced white matter lesions. <i>Neurochemistry International</i> , 2016, 94, 90-97.	1.9	18
41	Altered relaxin family receptors RXFP1 and RXFP3 in the neocortex of depressed Alzheimer's disease patients. <i>Psychopharmacology</i> , 2016, 233, 591-598.	1.5	14
42	Ageing and the telomere connection: An intimate relationship with inflammation. <i>Ageing Research Reviews</i> , 2016, 25, 55-69.	5.0	280
43	Extracellular vesicles are rapidly purified from human plasma by Protein Organic Solvent Precipitation (PROSPR). <i>Scientific Reports</i> , 2015, 5, 14664.	1.6	99
44	Differential Alterations of Neocortical GluN Receptor Subunits in Patients with Mixed Subcortical Ischemic Vascular Dementia and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 431-437.	1.2	4
45	Markers of Cardiac Dysfunction in Cognitive Impairment and Dementia. <i>Medicine (United States)</i> , 2015, 94, e297.	0.4	60
46	Cystathionine $\beta$ -Synthase Inhibition Is a Potential Therapeutic Approach to Treatment of Ischemic Injury. <i>ASN Neuro</i> , 2015, 7, 175909141557871.	1.5	32
47	F-box protein 7 mutations promote protein aggregation in mitochondria and inhibit mitophagy. <i>Human Molecular Genetics</i> , 2015, 24, 6314-6330.	1.4	64
48	Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias. <i>Brain Pathology</i> , 2015, 25, 401-408.	2.1	144
49	Andrographolide attenuates interleukin-1 $\beta$ -stimulated upregulation of chemokine CCL5 and glial fibrillary acidic protein in astrocytes. <i>NeuroReport</i> , 2014, 25, 881-886.	0.6	7
50	Decreased immunoreactivities of neocortical AMPA receptor subunits correlate with motor disability in Lewy body dementias. <i>Journal of Neural Transmission</i> , 2014, 121, 71-78.	1.4	3
51	Serotonergic Therapies for Cognitive Symptoms in Alzheimer's Disease: Rationale and Current Status. <i>Drugs</i> , 2014, 74, 729-736.	4.9	77
52	iTRAQ Quantitative Clinical Proteomics Revealed Role of Na <sup>+</sup> K <sup>+</sup> -ATPase and Its Correlation with Deamidation in Vascular Dementia. <i>Journal of Proteome Research</i> , 2014, 13, 4635-4646.	1.8	31
53	Decreased rabphilin 3A immunoreactivity in Alzheimer's disease is associated with $\beta^2$ burden. <i>Neurochemistry International</i> , 2014, 64, 29-36.	1.9	41
54	The brain lipidomes of subcortical ischemic vascular dementia and mixed dementia. <i>Neurobiology of Aging</i> , 2014, 35, 2369-2381.	1.5	77

#	ARTICLE	IF	CITATIONS
55	Novel pathophysiological markers are revealed by iTRAQ-based quantitative clinical proteomics approach in vascular dementia. <i>Journal of Proteomics</i> , 2014, 99, 54-67.	1.2	30
56	Autoantibodies to GM1 and GQ1b $\pm$ are not Biological Markers of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 1165-1169.	1.2	10
57	Genome-wide profiling of alternative splicing in Alzheimer's disease. <i>Genomics Data</i> , 2014, 2, 290-292.	1.3	18
58	NeuroAiD $\text{\textcircled{R}}$ (MLC601) and Amyloid Precursor Protein Processing. <i>Cerebrovascular Diseases</i> , 2013, 35, 30-37.	0.8	10
59	Preservation of cortical histamine H3 receptors in ischemic vascular and mixed dementias. <i>Journal of the Neurological Sciences</i> , 2012, 315, 110-114.	0.3	6
60	Upregulation of AMPA receptor GluR2 (GluA2) subunits in subcortical ischemic vascular dementia is repressed in the presence of Alzheimer's disease. <i>Neurochemistry International</i> , 2011, 58, 820-825.	1.9	14
61	Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer's disease. <i>Psychopharmacology</i> , 2011, 213, 431-439.	1.5	39
62	Genome wide profiling of altered gene expression in the neocortex of Alzheimer's disease. <i>Journal of Neuroscience Research</i> , 2010, 88, 1157-1169.	1.3	108
63	Hippocampal neurofibrillary tangle changes and aggressive behaviour in dementia. <i>NeuroReport</i> , 2010, 21, 1111-1115.	0.6	20
64	Cdk5-Mediated Phosphorylation of $\beta$ -Catenin Regulates Its Localization and GluR2-Mediated Synaptic Activity. <i>Journal of Neuroscience</i> , 2010, 30, 8457-8467.	1.7	27
65	A serotonergic basis for hyperphagic eating changes in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2010, 288, 151-155.	0.3	38
66	Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex. <i>Neurochemistry International</i> , 2010, 57, 985-989.	1.9	59
67	Neurochemical basis for symptomatic treatment of Alzheimer's disease. <i>Neuropharmacology</i> , 2010, 59, 221-229.	2.0	94
68	Altered NCAM Expression Associated with the Cholinergic System in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 659-668.	1.2	38
69	Characterization of histamine H <sub>3</sub> receptors in Alzheimer's Disease brain and amyloid overexpressing TASTPM mice. <i>British Journal of Pharmacology</i> , 2009, 157, 130-138.	2.7	50
70	Loss of [3H]4-DAMP binding to muscarinic receptors in the orbitofrontal cortex of Alzheimer's disease patients with psychosis. <i>Psychopharmacology</i> , 2008, 198, 251-259.	1.5	17
71	Selective loss of P2Y2 nucleotide receptor immunoreactivity is associated with Alzheimer's disease neuropathology. <i>Journal of Neural Transmission</i> , 2008, 115, 1165-1172.	1.4	49
72	Alterations in NMDA receptor subunit densities and ligand binding to glycine recognition sites are associated with chronic anxiety in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2008, 29, 1524-1532.	1.5	21

#	ARTICLE	IF	CITATIONS
73	Involvement of an Altered 5-HT <sub>6</sub> Receptor Function in Behavioral Symptoms of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2008, 14, 43-50.	1.2	39
74	Disrupted muscarinic M1 receptor signaling correlates with loss of protein kinase C activity and glutamatergic deficit in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2007, 28, 1381-1387.	1.5	31
75	Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 1110-1117.	1.5	56
76	Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 1216-1223.	1.5	85
77	Selective effects of the APOE $\epsilon$ 4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2006, 22, 555-561.	2.1	26
78	Loss of serotonin 5-HT <sub>2A</sub> receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease. <i>Psychopharmacology</i> , 2005, 179, 673-677.	1.5	83
79	[ <sup>3</sup> H]GR113808 binding to serotonin 5-HT <sub>4</sub> receptors in the postmortem neocortex of Alzheimer disease: a clinicopathological study. <i>Journal of Neural Transmission</i> , 2003, 110, 779-788.	1.4	26
80	Reduced serotonin 5-HT <sub>1A</sub> receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. <i>Brain Research</i> , 2003, 974, 82-87.	1.1	141
81	Serotonin transporters are preserved in the neocortex of anxious Alzheimer's disease patients. <i>NeuroReport</i> , 2003, 14, 1297-1300.	0.6	2
82	Serotonin transporters are preserved in the neocortex of anxious Alzheimer's disease patients. <i>NeuroReport</i> , 2003, 14, 1297-1300.	0.6	19
83	Postmortem serotonergic correlates of cognitive decline in Alzheimer's disease. <i>NeuroReport</i> , 2002, 13, 1175-1178.	0.6	84
84	Psychosis of Alzheimer's disease is associated with elevated muscarinic M <sub>2</sub> binding in the cortex. <i>Neurology</i> , 2001, 57, 805-811.	1.5	106